Treatment-resistant depression, often called TRD, affects many people who do not respond to traditional antidepressants. These individuals may spend months or years trying medications, psychotherapy, and other interventions without meaningful relief. This ongoing struggle has highlighted the urgent need for faster acting and longer-lasting treatment options. A recent study on inhaled psychedelic therapy offers a potential new path forward, showing rapid improvements within hours and continued benefits for months.
A New Approach to Psychedelic Treatment
The investigational treatment, known as GH001, is a vaporized synthetic form of the psychedelic compound mebufotenin. Unlike other psychedelic-assisted therapies that involve extended periods of altered perception and require long supervision times, this inhaled psychedelic therapy creates a very short, intense experience that resolves quickly. In the study, most patients were ready for discharge within about an hour of treatment.
GH001 works by activating serotonin receptors involved in mood regulation. While many antidepressants also affect serotonin, they usually take several weeks to show meaningful changes. In contrast, participants in this research reported notable improvements within just two hours of receiving GH001.
Rapid and Significant Clinical Results
The phase 2b clinical trial included adults with treatment-resistant depression who had experienced an ongoing depressive episode for nearly a year on average. Participants received either GH001 or a placebo. The treatment involved a personalized schedule of up to three escalating inhaled doses administered over the course of a single day.
By day 8 of the trial, the results were striking. About 60 percent of the patients who received GH001 met criteria for a strong clinical response, and nearly 58 percent achieved remission. Meanwhile, none of the participants in the placebo group reached response or remission. This difference suggests that inhaled psychedelic therapy may have a uniquely fast and robust antidepressant effect.
Long-Lasting Impact with Flexible Dosing
All participants later joined a six-month open-label extension where they could receive additional individualized dosing if needed. Many required only a few additional treatments during that time. After six months, about 73 percent of participants remained in remission. This sustained benefit is particularly meaningful because maintaining long-term improvement is often one of the biggest challenges in TRD treatment.
Safety and Experience
Most reported side effects were mild or moderate. Some participants experienced symptoms such as nausea, tingling sensations, headache, or muscle tension. Importantly, there were no signs of increased suicidal thoughts or behavior, and no concerning effects on breathing despite the treatment being inhaled.
The psychedelic experience itself was short, lasting around 11 minutes on average. This is significantly shorter than the experiences associated with psilocybin or MDMA assisted therapy, which can take several hours. The brief duration of the psychoactive effects may make inhaled psychedelic therapy easier to integrate into clinical environments that require efficient patient flow and clear safety monitoring.
What This Means for the Future of TRD Treatment
Inhaled psychedelic therapy is still being studied, and more research is needed before it becomes widely available. However, the early results are encouraging. The combination of rapid relief, extended benefit, and a short treatment session offers a promising new direction for psychiatric care. If confirmed through larger trials, GH001 and similar approaches may provide clinicians with a powerful option for patients who have not found help through traditional therapies.
Citations
- ClinicalTrials.gov. GH001 in Treatment Resistant Depression (NCT05469241). https://clinicaltrials.gov/study/NCT05469241
- Reiff CM, et al. Psychedelic-Assisted Psychotherapy for Major Depressive Disorder. Current Psychiatry Reports. https://pubmed.ncbi.nlm.nih.gov/37270061/